Can Stem Cells Help With Chronic Pancreatitis?

Chronic pancreatitis is a progressive, often debilitating disease marked by irreversible scarring of the pancreas, relentless abdominal pain, and gradual loss of digestive and hormonal function. Because existing treatments mostly manage symptoms rather than reverse the underlying damage, researchers have begun testing mesenchymal stem cells (MSCs) as a way to calm the inflammation and fibrosis driving the disease. This article explains the biological rationale, summarizes what animal and early human studies actually show, and is honest about where the evidence stops: this is an investigational approach, not an approved or proven treatment.

Chronic Pancreatitis: A Brief Overview

Chronic pancreatitis develops when repeated or sustained injury to the pancreas — most often from long-term alcohol use, smoking, gallstones, genetic mutations, autoimmune disease, or duct obstruction — triggers a cycle of inflammation and scar tissue (fibrosis) that doesn't heal. Over time, this destroys the cells that produce digestive enzymes and insulin, leading to malnutrition, diabetes, and chronic, often severe pain that is notoriously difficult to control. Current management leans on enzyme replacement, pain medication, lifestyle changes, endoscopic duct procedures, and, in severe cases, surgery — including total pancreatectomy with islet autotransplantation. None of these reverses the underlying fibrosis, fueling interest in cell-based approaches.

How It's Thought to Work

MSCs are not expected to regenerate destroyed pancreatic tissue outright. Instead, the working hypothesis is that they act through paracrine signaling — secreting proteins, vesicles, and microRNAs that dial down inflammatory immune cells, interrupt the fibrotic signaling that lays down scar tissue, and protect remaining pancreatic cells from further injury. Some research groups have gone a step further, engineering MSCs (or the extracellular vesicles they release) to overexpress alpha-1 antitrypsin (AAT), a natural anti-inflammatory and antifibrotic protein, in an effort to amplify these effects specifically in pancreatic tissue.

What the Evidence Shows

The evidence base here is still almost entirely preclinical, but it is real, specific to chronic pancreatitis, and worth taking seriously as early-stage science.

In a mouse model of chemically induced chronic pancreatitis, extracellular vesicles from AAT-overexpressing MSCs reduced key fibrosis markers (α-SMA, TGF-β1, MMP2), restored a protective antioxidant pathway disrupted in diseased pancreatic tissue, and lowered pain-signaling gene expression and immune infiltration around pancreatic nerves — a promising, mechanistically detailed signal that this approach can blunt both the fibrotic and pain-generating sides of the disease in animals (PMC, 2021). Separately, human umbilical cord–derived MSCs improved markers of chronic pancreatitis in a rat model via the AKT-mTOR-S6K1 signaling pathway, adding a second, independent line of animal evidence pointing in the same direction (PMC, 2022).

Human data, however, are limited to early-phase safety trials that are still recruiting, with no published efficacy results yet. The U.S. Department of Veterans Affairs is sponsoring a Phase 1 crossover trial testing autologous (the patient's own) bone marrow-derived MSCs against placebo in patients with chronic pancreatitis pain (ClinicalTrials.gov NCT05925036). The Medical University of South Carolina is separately running an early-phase trial of allogeneic (donor-derived) bone marrow MSCs for the same indication (ClinicalTrials.gov NCT06205342). Both are designed primarily to establish safety and feasibility, not to confirm a benefit — and neither has reported results. No MSC-based therapy is FDA-approved for chronic pancreatitis, and none should be assumed safe or effective for this condition outside a regulated trial.

Who Might Be a Candidate

Because this remains experimental, "candidacy" today realistically means candidacy for a clinical trial, not for a marketed treatment. People who may want to discuss trial eligibility with their gastroenterologist or a study team include those who:

• Have a confirmed diagnosis of chronic pancreatitis with persistent pain despite standard pain management, enzyme replacement, and lifestyle changes
• Have not found adequate relief from endoscopic or surgical options, or are not candidates for them
• Are interested in contributing to research on cell-based, anti-fibrotic approaches rather than seeking a guaranteed outcome
• Meet the specific inclusion criteria (diagnosis confirmation, imaging, prior treatment history) listed on the relevant ClinicalTrials.gov record

Anyone considering this route should verify trial status directly on ClinicalTrials.gov and discuss risks with their own physician, since early-phase trials are designed to test safety first.

Bottom Line

The biology behind using MSCs for chronic pancreatitis is plausible, and early animal studies — particularly work on engineered, AAT-enriched MSC products — show genuinely encouraging reductions in fibrosis and pain-related signaling in rodent models. That said, this is still a preclinical-to-early-human story: two relevant trials are open and recruiting, but neither has reported whether the therapy actually helps patients, and there is no FDA-approved stem cell treatment for chronic pancreatitis. Patients should treat this as a promising research direction worth watching, not an available therapy, and should be cautious of any clinic offering MSC injections for chronic pancreatitis outside a registered trial.